Circadian Technologies (ASX:CIR) has received a tax refund of $2.2 million from the Australian Taxation Office relating to research and development expenditure in the 2014 financial year.
This relates to Australian and eligible overseas expenditure on the development of its lead molecule OPT-302 and its Phase 2 ready oncology asset VGX-100.
The tax refund strengthens the company’s balance sheet and assist in progressing the OPT-302 program through Phase 1 and 2 clinical studies.
OPT-302 is a treatment for ophthalmic diseases including wet age-related macular degeneration.
Circadian Technologies (ASX:CIR) has received a tax refund of...
Add to My Watchlist
What is My Watchlist?